Abstract |
In previous studies we have shown that combined chemo- immunotherapy of L1210 leukemia with IL-12 and doxorubicin results in striking anti- tumor effects producing 100% of long-term survivors. In this study we investigated the efficacy of a combination of IL-12 and mitoxantrone in murine L1210 leukemia. Mice inoculated with 1x105 leukemia cells were treated with a single dose of mitoxantrone and seven daily doses of IL-12, and were daily observed for survival. Treatment with IL-12 or mitoxantrone given alone produced moderate anti-leukemic effects. However, combination of both drugs resulted in a significant prolongation of mouse survival time. Importantly, there were almost 50% of long-term (>60 days) survivors among the mice treated with both agents. This therapeutic effect was completely abrogated by sub-lethal, whole-body X-irradiation, and significantly reduced after macrophage depletion.
|
Authors | J Golab, R Zagozdzon, K Kozar, R Kaminski, A Giermasz, T Stoklosa, W Lasek, M Jakobisiak |
Journal | Oncology reports
(Oncol Rep)
2000 Jan-Feb
Vol. 7
Issue 1
Pg. 177-81
ISSN: 1021-335X [Print] Greece |
PMID | 10601614
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Interleukin-12
- Mitoxantrone
|
Topics |
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Drug Synergism
- Interleukin-12
(administration & dosage)
- Leukemia L1210
(drug therapy)
- Macrophages
(physiology)
- Mice
- Mitoxantrone
(administration & dosage)
|